Agroaxis sprouted as an innovating idea from the founder member, who owns a deep market insight thanks to more than 35 years experience in the biopharmaceutical field. The company was established in 2010 and just three years, the company is nominated as the ten top in the word as biosimilar`s with the support of the European Union, Public Administration, through founding aimed at the development of R&D SMEsCurrently, it also boasts its own Research Center, 3200 m2, located in the Parque Tecnologico Tecnobahia Puerto de Santa Maria (Spain). Additionally, it is working in laboratory situated in El Puerto de Santa María (Spain).
Agroaxis is currently the only one company in Spain that is integrated from bench to production and commercialization of biosimilars, among other therapeutic proteins, through a plant based protein expression system.
The vision of Agroaxis is to become the reference in the pharmaceutical sector regarding the production and commercialization of nutraceutics and CMO services. It aims at being a leading company in its area, both on the national and international scale, thanks to its commitment with the high quality standards of its products and services.
The mission of the company is the research, development, production and distribution of pharmaceutic and biopharmaceutic products and services. It has specialized in the production of therapeutic proteins. To this aim, Agroaxis has developed highly competitive processes of molecular biology that are based on expression systems, industrial scale plant culture, extraction and purification of proteins., all this using plant biofactories.
The values that integrate the Agroaxis culture are focused on directing the whole company to address the client´s requirements: leadership, integrity, flexibility and efficiency.
Agroaxis´ staff is integrated by 8 people. 90% of them are exclusively devoted to R&D&I and everyone were hired through the INNCORPORA TU and INNCORPORA FPGS, programs, which are aimed at the recruitment of qualified staff.


More on Agroaxis

The advances in molecular biology and more particularly recombinant DNA technology has allowed nutritionally valuable products, healthcare and industry , can be produced in large quantities at low cost and with increased biosafety.
The idea of using plant systems for the production of recombinant proteins has ceased to be a challenge to become a reality and alternative for the biopharmaceutical industry.

AGROAXIS decided to use and adapt the System NGS® to all their technology platforms to respond to the growing need of a new culture technologies and as a result of water scarcity and soil low yields increasingly overexploited.

Latest News

  • Agroaxis hires three more technologists with the grant Inncorpora TU of the Ministry of Economy and Competitiveness
  • Agroaxis creates the first GreenMab® technology platform with plants Snuff “Human “Insulin for obtaining

    Copyright 2013 Agroaxis. All Rights Reserved